Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer

Cancer Science

Volumn 106, Issue 12, 2015, Pages 1687-1692

  Yamaguchi, Hiroyuki ^a,b   Kawazu, Masahito ^a   Yasuda, Takahiko ^a   Soda, Manabu ^a   Ueno, Toshihide ^a   Kojima, Shinya ^a   Yashiro, Masakazu ^c   Yoshino, Ichiro ^d   Ishikawa, Yuichi ^e   Sai, Eirin ^a   Mano, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e CANCER INSTITUTE   (Japan)

Author keywords

Cancer genomics; Mammalian target of rapamycin; Molecularly targeted therapy; Oncogene; Somatic mutation

Indexed keywords

ATM PROTEIN; EUKARYOTIC TRANSLATION INITIATION FACTOR 4E BINDING PROTEIN 1; LEUCINE; PROTEIN; PROTEIN FRAP; PROTEIN S6; PROTEIN TRRAP; S6 KINASE; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG; VALINE; MTOR PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL NEUROENDOCRINE CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; 3T3 CELL LINE; ANIMAL; CELL TRANSFORMATION; GENETICS; MUTATION; NEOPLASM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

3T3 CELLS; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MICE; MUTATION; NEOPLASMS; ONCOGENES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOR SERINE-THREONINE KINASES;

EID: 84983156942     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12828     Document Type: Article

References (17)

1. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005; 17: 596-603.
2. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5: 921-9.
3. Xu K, Liu P, Wei W. mTOR signaling in tumorigenesis. Biochim Biophys Acta 2014; 1846: 638-54.
4. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-45.
5. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-34.
6. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-62.
7. Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M, Tamanoi F. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci USA 2007; 104: 3514-9.
8. Ohne Y, Takahara T, Hatakeyama R et al. Isolation of hyperactive mutants of mammalian target of rapamycin. J Biol Chem 2008; 283: 31861-70.
9. Murugan AK, Alzahrani A, Xing M. Mutations in critical domains confer the human mTOR gene strong tumorigenicity. J Biol Chem 2013; 288: 6511-21.
10. Sekulic A, Hudson CC, Homme JL et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000; 60: 3504-13.
11. Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 2010; 29: 2746-52.
12. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. Br J Cancer 1995; 72: 1200-10.
13. Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci Signal 2005; 2005: pe4.
14. Jacinto E, Loewith R, Schmidt A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-8.
15. Hung CM, Garcia-Haro L, Sparks CA, Guertin DA. mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol 2012; 4: a008771.
16. Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-68.
17. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature 2013; 497: 217-23.